Allianz Asset Management
CRNX icon

Allianz Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Allianz Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,400
Closed -$839K – 2231
2024
Q4 		$839K Buy
16,400
+2,200
+15% +$123K ﹤0.01% 1690
2024
Q3 		$726K Buy
14,200
+6,300
+80% +$325K ﹤0.01% 1741
2024
Q2 		$354K Buy
7,900
+3,000
+61% +$139K ﹤0.01% 1932
2024
Q1 		$229K Sell
4,900
-7,800
-61% -$305K ﹤0.01% 1820
2023
Q4 		$452K Buy
+12,700
New +$389K ﹤0.01% 1883

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz Asset Management's CRNX Position: Q1 2025 in Review

Allianz Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 16,400 shares — an estimated $839K sold.

Allianz Asset Management first reported a position in CRNX in Q4 2023 and held it in 5 quarters. The position peaked at $839K in Q4 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • Allianz Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Allianz Asset Management sold 16,400 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $839K.
  • Allianz Asset Management first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Allianz Asset Management's Crinetics Pharmaceuticals position peaked at $839K in Q4 2024.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Allianz Asset Management's 13F filing for Q1 2025, filed 5 May 2025.